Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04846829 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)
A Early Phase 1 study of Major Depressive Disorder, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04846829 is a Early Phase 1 study of Major Depressive Disorder that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04846829, a Early Phase 1 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will recruit 30 subjects diagnosed with Major Depressive Disorder (MDD). Subjects will be recieve one infusion treatment of citalopram or placebo and 10 treatments of a form of transcranial magnetic stimulation, theta burst stimulation (TBS). Subjects will also undergo brain scans, quantitative electroencephalography (qEEG) brain activity recordings, and mood surveys. Study activities will be performed over the course of 4 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DEVICE intermittent theta burst stimulation
- DRUG intravenous citalopram hydrochloride (CIT)
- DEVICE continuous theta burst stimulation
Study Locations (1)
California
- UCLA Depression Research and Clinic Program - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2028-04-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04846829
The ClinicalTrials.gov registry entry for NCT04846829 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (92% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04846829 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04846829 about?
NCT04846829 is a clinical study titled "Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)". This study will recruit 30 subjects diagnosed with Major Depressive Disorder (MDD). Subjects will be recieve one infusion treatment of citalopram or placebo and 10 treatments of a form of transcranial magnetic stimulation, theta burst stimulation (TBS). Subjects will also undergo brain scans, quanti...
What is the current status of trial NCT04846829?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-04-24. Estimated completion is 2028-04-24.
What conditions does trial NCT04846829 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT04846829?
The interventions under investigation include: Placebo (DRUG), intermittent theta burst stimulation (DEVICE), intravenous citalopram hydrochloride (CIT) (DRUG), continuous theta burst stimulation (DEVICE).
Who is sponsoring clinical trial NCT04846829?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04846829 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Mood Effects of Serotonin Agonists: Depression
RECRUITING · Early Phase 1
-
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
RECRUITING · Early Phase 1
-
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
ACTIVE NOT RECRUITING · Early Phase 1
-
Testing a Transdiagnostic TMS Treatment Target
ACTIVE NOT RECRUITING · Early Phase 1
-
Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.